BMY-25271

Cat. No.:	HY-100191
CAS No.:	78441-82-4
Molecular Formula:	$C_{12}H_{19}N_5O_2S_2$
Molecular Weight:	329.44
Target:	Histamine Receptor
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BMY-25271 is a histamine H2 receptor antagonist.
IC_{50} & Target	Histamine H2 receptor[1]
In Vivo	BMY-25271 is a histamine H2 receptor antagonist. The dose response curves are parallel and oral ED_{50} values derived from probit analysis are 0.093, 0.97 and 6.9 mg/kg for BMY-25271, ranitidine and cimetidine, respectively. BMY-25271, therefore, is about 10 and 74 times more potent than ranitidine and cimetidine, respectively. Pretreatment with the highest dose of BMY-25271 does not significantly affect the absorption of aspirin or the formation of its major metabolite, salicylic acid[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration [1]	Five beagle dogs are used in this study. Vehicle or BMY-25271 (0.4 mg/kg) is administered orally 1 h before aspirin (100 mg/kg). Blood samples are collected from the jugular vein just before aspirin administration and 30, 60, 90 and 120 min after aspirin administration. One week later, the dogs are crossed over, and the study is repeated[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Cavanagh RL, et al. Prevention of aspirin-induced gastric mucosal injury by histamine H2 receptor antagonists: a crossover endoscopic and intragastric pH study in the dog. J Pharmacol Exp Ther. 1987 Dec;243(3):1179-84.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA